Additionally, since our study was focused on the effects of EGFR-TKI combined chemotherapy on immune function, tumor markers and oxidative stress, it did not address the effect of the treatment on the incidence of adverse reactions and overall survival rate. This evidence concerns the gene EGFR and neoplasm.